Terms: = Liver cancer AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Prognosis
118 results:
1. Early Onset Intrahepatic Cholangiocarcinoma: Clinical Characteristics, Oncological Outcomes, and Genomic/Transcriptomic Features.
Tsilimigras DI; Han X; Guglielmi A; Aldrighetti L; Weiss M; Bauer TW; Alexandrescu S; Poultsides GA; Maithel SK; Marques HP; Martel G; Pulitano C; Shen F; Chaucy F; Koerkamp BG; Endo I; Sasaki K; Aucejo F; Zhang XF; Zhu H; Pawlik TM
Ann Surg Oncol; 2024 May; 31(5):3087-3097. PubMed ID: 38347332
[TBL] [Abstract] [Full Text] [Related]
2. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
3. The Prognostic and Therapeutic Roles of ARL-6 Gene in Hepatocellular Carcinoma.
Wang J; Che F; Zhao Y; Wei L; Chen D; Dai C; Zhang B; Zhou X; Yang B; Chen Z
Int J Med Sci; 2024; 21(2):207-218. PubMed ID: 38169538
[No Abstract] [Full Text] [Related]
4. Crosstalk of cuproptosis-related prognostic signature and competing endogenous RNAs regulation in hepatocellular carcinoma.
Zhu J; Wang J; Liu H; Lei T; Yang J; Lan S; Jian H; Fang H; Zhang Y; Ren K; Zhong F
Aging (Albany NY); 2023 Dec; 15(23):13901-13919. PubMed ID: 38078880
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China.
Ren M; Cai X; Jia L; Bai Q; Zhu X; Hu X; Wang Q; Luo Z; Zhou X
BMC Cancer; 2023 Dec; 23(1):1175. PubMed ID: 38041048
[TBL] [Abstract] [Full Text] [Related]
6. Cuproptosis-related prognostic signatures predict the prognosis and immunotherapy in HCC patients.
Peng H; Zou Z; Xiang Z; Lu X; Zhang Y; Peng X
Medicine (Baltimore); 2023 Aug; 102(34):e34741. PubMed ID: 37653738
[TBL] [Abstract] [Full Text] [Related]
7. EBV-Positive Inflammatory Follicular Dendritic Cell Sarcoma of the Spleen: Report of an Aggressive Form With Molecular Characterization.
Baber A; Legendre P; Palmic P; Lupo-Mansuet A; Burroni B; Azoulay C; Szwebel TA; Costedoat-Chalumeau N; Leroy K; Blons H; Blay JY; Boudou-Rouquette P; Terrier B
Int J Surg Pathol; 2024 Feb; 32(1):150-154. PubMed ID: 37157817
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
[TBL] [Abstract] [Full Text] [Related]
9. Primary and secondary angiosarcomas of the liver: a multi-institutional study of 32 cases.
Liao X; Lai J; Lin J; Zhang D
Hum Pathol; 2023 Jul; 137():10-17. PubMed ID: 37054784
[TBL] [Abstract] [Full Text] [Related]
10. Cuproptosis regulatory genes greatly contribute to clinical assessments of hepatocellular carcinoma.
Ke C; Dai S; Xu F; Yuan J; Fan S; Chen Y; Yang L; Li Y
BMC Cancer; 2023 Jan; 23(1):25. PubMed ID: 36611155
[TBL] [Abstract] [Full Text] [Related]
11. Ezrin accelerates breast cancer liver metastasis through promoting furin-like convertase-mediated cleavage of Notch1.
Chen M; Pan Y; Liu H; Ning F; Lu Q; Duan Y; Gan X; Lu S; Hou H; Zhang M; Tian Y; Lash GE
Cell Oncol (Dordr); 2023 Jun; 46(3):571-587. PubMed ID: 36580262
[TBL] [Abstract] [Full Text] [Related]
12. Exploring the mechanisms underlying the therapeutic effect of the
Qing L; Pan B; He Y; Liu Y; Zhao M; Niu B; Gao X
Aging (Albany NY); 2022 Nov; 14(22):9103-9127. PubMed ID: 36403263
[TBL] [Abstract] [Full Text] [Related]
13. Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targets.
Fujita M; Chen MM; Siwak DR; Sasagawa S; Oosawa-Tatsuguchi A; Arihiro K; Ono A; Miura R; Maejima K; Aikata H; Ueno M; Hayami S; Yamaue H; Chayama K; Lee JS; Lu Y; Mills GB; Liang H; Nishizuka SS; Nakagawa H
Nat Commun; 2022 Oct; 13(1):6481. PubMed ID: 36309506
[TBL] [Abstract] [Full Text] [Related]
14. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
Yan C; Niu Y; Ma L; Tian L; Ma J
J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
[TBL] [Abstract] [Full Text] [Related]
15. Tumor-Promoting Actions of HNRNP A1 in HCC Are Associated with Cell Cycle, Mitochondrial Dynamics, and Necroptosis.
Zhao B; Lv X; Zhao X; Maimaitiaili S; Zhang Y; Su K; Yu H; Liu C; Qiao T
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142139
[TBL] [Abstract] [Full Text] [Related]
16. Precision oncology for intrahepatic cholangiocarcinoma in clinical practice.
Tomczak A; Springfeld C; Dill MT; Chang DH; Kazdal D; Wagner U; Mehrabi A; Brockschmidt A; Luedde T; Naumann P; Stenzinger A; Schirmacher P; Longerich T
Br J Cancer; 2022 Nov; 127(9):1701-1708. PubMed ID: 35986087
[TBL] [Abstract] [Full Text] [Related]
17. RNF2 mediates pulmonary fibroblasts activation and proliferation by regulating mTOR and p16-CDK4-Rb1 signaling pathway.
Pan L; Hu Y; Qian C; Yao Y; Wang S; Shi W; Xu T
Inflamm Res; 2022 Nov; 71(10-11):1283-1303. PubMed ID: 35933565
[TBL] [Abstract] [Full Text] [Related]
18. ink4 cyclin-dependent kinase inhibitors as potential prognostic biomarkers and therapeutic targets in hepatocellular carcinoma.
Liu H; Jia S; Guo K; Li R
Biosci Rep; 2022 Jul; 42(7):. PubMed ID: 35771229
[TBL] [Abstract] [Full Text] [Related]
19. Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma.
Rimini M; Macarulla T; Burgio V; Lonardi S; Niger M; Scartozzi M; Rapposelli IG; Aprile G; Ratti F; Pedica F; Verdaguer H; Nappo F; Nichetti F; Lai E; Valgiusti M; Cappetta A; Febregat C; Fassan M; De Braud F; Puzzoni M; Frassineti GL; Simionato F; De Cobelli F; Aldrighetti L; Fornaro L; Cascinu S; Casadei-Gardini A
Eur J Cancer; 2022 Aug; 171():232-241. PubMed ID: 35749808
[TBL] [Abstract] [Full Text] [Related]
20. Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies.
Fu Y; Yang Z; Hu Z; Yang Z; Pan Y; Chen J; Wang J; Hu D; Zhou Z; Xu L; Chen M; Zhang Y
Hepatol Int; 2022 Aug; 16(4):868-878. PubMed ID: 35674872
[TBL] [Abstract] [Full Text] [Related]
[Next]
